Plain-English translation of NCT06237920 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two immunotherapy drugs— and —works better than alone in treating advanced bladder cancer before surgery. You would receive two doses of your assigned medication (given 28 days apart) before undergoing bladder removal surgery. The goal is to see if this pre-surgery immunotherapy helps more patients achieve a complete cancer response.
Currently, people with advanced bladder cancer who cannot or choose not to receive traditional chemotherapy have limited options before surgery. This trial is exploring whether this immunotherapy combination can help shrink or eliminate cancer before surgery, potentially improving long-term survival and quality of life.
You would visit the clinic twice, about 28 days apart, to receive intravenous infusions of your assigned treatment. After both doses, you'll have imaging scans (MRI and CT) to check how the cancer has responded, and then you'll proceed to bladder removal surgery. Follow-up visits occur at 6, 12, and 24 months after treatment to monitor for recurrence, side effects, and quality of life—including how your bladder function and overall well-being are affected.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Netherlands